Figure 4
Systemic pan-FGFR blockade protects diabetic mice from cardiac hypertrophy. Three-month old ob/ob and wildtype mice were injected daily with 1 mg/kg PD173074 or vehicle solution for six weeks followed by endpoint analysis. (a) Body weight, (b) blood glucose levels, and (c) serum FGF21 levels. (d) Representative images of H&E-stained transverse heart sections (scale bar = 2 mm) and (e) quantification of the thickness of the LV wall in these images. (f) Wheat germ agglutinin-stained LV tissue (scale bar = 25 µm), and (g) quantification of cardiac myocyte area. Comparison between groups was performed in form of a one-way ANOVA followed by a post-hoc Tukey test (a–c, e, g). All values are expressed as mean ± SEM. (a–c, e, g) N = 4–5, *p ≤ 0.05 vs. WT, &p ≤ 0.05 vs. WT + PD173074 of same age, #p ≤ 0.05 vs. ob/ob of same age.
